Volume 20

Issue 1

Article 57

2012

Targeting inflammatory pathways by dietary agents for prevention
and therapy of cancer

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Aggarwal, B.B.; Prasad, S.; Yadav, V.R.; Park, B.; Kim, J.H.; Gupta, S.C.; Yoon, S.W.; Lavasanifar, A.; and
Sung, B. (2012) "Targeting inflammatory pathways by dietary agents for prevention and therapy of cancer,"
Journal of Food and Drug Analysis: Vol. 20 : Iss. 1 , Article 57.
Available at: https://doi.org/10.38212/2224-6614.2123

This Conference Paper is brought to you for free and open access by Journal of Food and Drug Analysis. It has
been accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and
Drug Analysis.

Journal of Food and Drug Analysis, Vol. 20, Suppl. 1, 2012, Pages 231-236

藥物食品分析

第二十卷

ICoFF論文集

231

Targeting Inflammatory Pathways by Dietary Agents For
Prevention and Therapy of Cancer
BHARAT B. AGGARWAL*, SAHDEO PRASAD, VIVEK R. YADAV, BYOUNGDUCK PARK, JI HYE KIM,
SUBASH C. GUPTA, SEONG WOO YOON, AFSANEH LAVASANIFAR AND BOKYUNG SUNG
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center,
Texas, U.S.A.

ABSTRACT
Chronic infections, obesity, alcohol, tobacco, radiation, environmental pollutants, and high-calorie diet have been recognized
as major risk factors for the most common types of cancers. All these risk factors are linked to cancer through inflammation.
While acute inflammation that persists for short-term mediates host defense against infections, chronic inflammation that lasts for
long-term can predispose the host to various chronic illnesses, including cancer. Linkage between cancer and inflammation is
indicated by numerous lines of evidence; first, transcription factors NF-B and STAT3, two major pathways for inflammation,
are activated by most cancer risk factors; second, an inflammatory condition precedes most cancers; third, NF-B and STAT3 are
constitutively active in most cancers; fourth, hypoxia and acidic conditions found in solid tumors activate NF-B; fifth,
chemotherapeutic agents and gamma irradiation activate NF-B and lead to chemo-resistance and radio-resistance; sixth, most
gene products linked to inflammation, survival, proliferation, invasion, angiogenesis, and metastasis are regulated by NF-B and
STAT3; seventh, suppression of NF-B and STAT3 inhibits the proliferation and invasion of tumors; and eighth, most
chemo-preventive agents mediate their effects through inhibition of NF-B and STAT3 activation pathways. Thus suppression of
these pro-inflammatory pathways may provide opportunities for both prevention and treatment of cancer. The potential of dietary
agents in regulation of these inflammatory cell signaling pathways and their role in prevention and therapy of cancer, is
discussed.
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INTRODUCTION
Common wisdom says “most things in life are a
double-edged sword”. While they are in our favor at one
dose or under one condition; they may be disfavor at
another dose or under another condition. This is analogous
to what Alexander Fleming (discoverer of penicillin) once
said: if the soil causes the disease; the cure to the disease
also lies in it. For instance, while TNF mediates
rheumatoid arthritis, the soluble form of its receptor
(enbrel) is used for its treatment. Similarly, while T helper
(Th)-1 secreted cytokines mediate inflammation, Th-2
produced cytokines suppress it. Also it is noted that
while pro-oxidants produced in the body mediate
inflammation, antioxidants (such as glutathione) suppress
this response. Inflammation is a part of the host response
to either internal or external environmental stimuli. This
response serves to counteract the insult incurred by these
stimuli to the host. This response can be pyrogenic, as
indicated by fever. When acute inflammation or fever is
manifested for a short period of time, it has a therapeutic
consequence. However, when inflammation becomes
chronic or lasts too long, it can prove harmful and may
lead to disease. How is inflammation diagnosed and its

biomarkers is not fully understood, however, the role of
pro-inflammatory cytokines, chemokines, adhesion
molecules and inflammatory enzymes have been linked
with chronic inflammation. Chronic inflammation has
been found to mediate a wide variety of diseases, including
cardiovascular diseases, cancer, diabetes, arthritis,
Alzheimer’s disease, pulmonary diseases, and autoimmune
diseases. The current review, however, will be restricted to
the role of chronic inflammation in cancer. Chronic
inflammation has been linked to various steps involved in
tumorigenesis,
including
cellular
transformation,
promotion, survival, proliferation, invasion, angiogenesis,
and metastasis. That inflammation is a risk factor for most
type of cancers is now well recognized. The present review
will discuss the various inflammatory intermediates
responsible for the steps leading to formation of tumors,
their growth and metastasis.
I.

NF-κB Activation Mediates Tumorigenesis

TNF, interleukins, chemokines, COX-2, 5-LOX, and
MMP-9 are all regulated by the transcription factor NF-κB.
Although this factor is expressed in an inactive state in
most cells, cancer cells express an activated form of
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NF-κB. This activation is induced by a wide variety of
inflammatory stimuli and carcinogens, and the gene
products regulated by it mediate tumorigenesis as
indicated above. Only few of the recent evidences linking
NF-κB and cancer will be reviewed here.
II. Genetic Evidence About the Role of NF-κB in
Tumorigenesis
NF-κB activity is triggered in response to infectious
agents and pro-inflammatory cytokines via the IκB kinase
(IKK) complex. Using a colitis-associated cancer model, it
has been shown that although deletion of IKKβ in
intestinal epithelial cells does not decrease inflammation, it
leads to a dramatic decrease in tumor incidence without
affecting tumor size. Pikarsky et al. reported that NF-κB
constitutes an important missing link between cancer and
inflammation. The Mdr2-knockout mouse strain, which
spontaneously develops cholestatic hepatitis followed by
hepatocellular carcinoma, serves as a prototype of
inflammation-associated cancer. It has been shown that the
inflammatory process triggers hepatocyte NF-κB through
upregulation of TNFα in adjacent endothelial and
inflammatory cells. Suppressing NF-κB inhibition through
anti-TNFα treatment or induction of IκB-super-repressor in
later stages of tumor development resulted in apoptosis of
transformed hepatocytes and failure to progress to
hepatocellular carcinoma.
Mice lacking IKKβ only in hepatocytes has been
found to exhibit a marked increase in hepatocarcinogenesis
caused by diethylnitrosamine (DEN). Decreased
hepatocarcinogenesis was also found in mice lacking
IKKβ in both hepatocytes and hematopoietic-derived
Kuffer cells. These mice exhibited reduced hepatocyte
regeneration and diminished induction of hepatomitogens,
which were unaltered in mice lacking IKKβ, suggesting
that IKKβ provides an inflammatory crosstalk between
hepatocytes and hematopoietic-derived cells that promote
chemical hepatocarcinogenesis. Co-culture of macrophages
with ovarian or breast cancer cell lines led to
TNFα-dependent activation of JNK and NF-κB pathways
in tumor cells but not in benign immortalized epithelial
cells. Tumor cells with increased JNK and NF-κB activity
exhibited enhanced invasiveness. Inhibition of the NF-κB
pathway by TNFα-neutralizing antibodies, an NF-κB
inhibitor, RNAi to RelA, or overexpression of IκB
inhibited tumor cell invasiveness. This suggests that
TNF-α, via NF-κB and JNK, induces macrophage
migratory inhibitory factor (MIF) and extracellular matrix
metalloproteinase inducer CD147 (EMMPRIN) in
macrophage to tumor cell co-cultures and leads to
increased invasive capacity of the tumor cells.
III. Activation of NF-κB by carcinogens
Cigarette smoke (CS) contains several carcinogens
known to initiate and promote tumorigenesis and
metastasis. Treatment of human histiocytic lymphoma
cells with CS activated NF-κB in a dose- and
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time-dependent manner. Thus CS can activate NF-κB in a
wide variety of cells, and this may play a role in cigarette
smoke-induced carcinogenesis. The role of EBV latent
infection in development of lymphoid and epithelial
malignancies such as nasopharyngeal carcinoma (NPC) is
mediated via NF-κB activation pathway. The EBV latent
membrane protein 1 (LMP1) acts as a constitutively active
tumor necrosis factor receptor and activates cellular
signaling pathways such as c-Jun-NH(2)-terminal kinase,
cdc42, Akt, and NF-κB. Activation of NF-κB p50
homodimer/Bcl-3 complexes has been found in
nasopharyngeal carcinoma. Constitutive activation of
NF-κB in human melanoma cells has been linked to
activation of Akt kinase suggesting that activation of Akt
may be an early marker for tumor progression in
melanoma. The chemokines CXC ligand 1 (CXCL1) and
CXCL8, but not CXCL5, are highly expressed in most
melanoma cell lines, suggesting that the constitutive
production of chemokines is highly correlated to
endogenous NF-κB activity. Dhawan’s group reported that
constitutive activation of Akt in melanoma leads to
upregulation of NF-κB and tumor progression.
Numerous studies have indicated that tumor cells
exhibit an elevation in constitutive production of the
pro-inflammatory cytokines TNF-α, IL-1α, IL-6, GM-CSF,
and KC (the murine homologue of chemokine Groα). The
basis for constitutive expression of these cytokines after
tumor progression in vivo is unknown. Regulation of the
expression of these pro-inflammatory cytokines involves
transcription factor NF-κB, which can be activated by
cytokines such as TNF-α. The host environment promotes
the constitutive activation of NF-κB and pro-inflammatory
cytokine expression during metastatic tumor progression
of murine squamous cell carcinoma. The gastric pathogen
Helicobacter pylori is associated with progression to
gastric cancer. H. pylori induces plasminogen activator
inhibitor 2 in gastric epithelial cells via activation of
NF-κB and RhoA, which in turn mediates invasion and
apoptosis.
Suganuma et al. found that H. pylori
membrane protein 1 (HP-MP1) induces release of
inflammatory cytokines and TNFα, which acts as both
initiator and tumor promoter, and produced tumors in nude
mice. Helicobacter infection has been shown to induce
inflammation and colon cancer in SMAD3-deficient mice.
Brandt and coworkers showed that the H pylori
immunodominant protein, CagA which causes gastritis and
carcinoma induces IL-8 in a dose and time dependent
manner
and
this
induction
occurs
via
a
Ras-->Raf-->Mek-->Erk-->NF-κB signaling pathway in a
Shp-2- and c-Met-independent manner.
Ⅳ.

NF-κB as a Growth Factor for Tumor Cells

The role of NF-κB as a growth factor for tumor cells
is well documented. Ludwig’s group investigated the role
of specific point mutations of the ret proto-oncogene in
multiple endocrine neoplasia (MEN) types 2A and 2B, for
familial medullary thyroid carcinoma (MTC) syndromes,
and for sporadic MTC. They found that NF-κB is
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constitutively active in C-cell carcinoma and is required
for ret-induced transformation. RET-induced NF-κB and
IKKβ activity requires Ras function but involves neither
the classical MAPK/ERK pathway nor the PI-3K/Akt
pathway. In contrast, RET-induced NF-κB activity is
dependent on Raf and MEKK1. Inhibition of constitutive
NF-κB activity results in cell death of TT cells and blocks
focus formation induced by oncogenic forms of RET in
NIH 3T3 cells. These results suggest that RET-mediated
carcinogenesis critically depends on IKK activity and
subsequent NF-κB activation. Constitutive activation of
NF-κB in human cutaneous T cell lymphoma cells was
mediated through the autocrine production of TNF.
Constitutive activation of NF-κB in human cutaneous T
cell lymphoma cell has been reported to mediate the
proliferation of these cells.
Breast cancer metastasis suppressor 1 (BRMS1)
functions as a metastasis-suppressor gene in breast cancer
and melanoma cell lines. BRMS1 inhibits gene expression
by targeting NF-κB. Suppression of both constitutive and
TNF-induced NF-κB activation by BRMS1 may be due to
inhibition of IκBα phosphorylation and degradation. These
results suggest that at least one of the underlying
mechanisms of BRMS1-dependent suppression of tumor
metastasis includes inhibition of NF-κB activity and
subsequent suppression of uPA expression in breast cancer
and melanoma cells. The antiapoptotic response and
enhanced cellular proliferation observed in neoplastic cells
on overexpression of metallothionein (MT) is also
mediated via NF-κB signaling pathway. MT caused
transactivation of NF-κB through a specific interaction
with the p50 subunit of NF-κB, thus mediating the
antiapoptotic effects of MT. Lack of molecular targets in
estrogen receptor-negative (ER-negative) breast cancer is a
major therapeutic hurdle. Biswas et al. studied NF-κB
activation in human breast cancer specimens and its role in
cell proliferation and apoptosis. These findings
substantiate the hypothesis that certain breast cancer cells
rely on NF-κB for aberrant cell proliferation and
simultaneously avoid apoptosis, thus implicating activated
NF-κB as a therapeutic target for distinctive subclasses of
ER-negative breast cancers.
Ⅴ.

NF-κB Suppression Mediates Chemosensitivity

Extensive research in the last few years suggests that
NF-κB activation mediates resistance to cytokines,
chemotherapeutic agents, and γ-irradiation, whereas
suppression of NF-κB can sensitize tumor cells to these
agents. For instance, it has been found that inhibition of
NF-κB activation confers sensitivity to TNF-α by
impairment of cell cycle progression in 6 human malignant
glioma cell lines. p65 DN protein was used to inhibit
NF-κB activation. Similarly, expression of a
dominant-negative mutant IκBα in human head and neck
squamous
cell
carcinoma
inhibits
survival,
pro-inflammatory cytokine expression, and tumor growth
in vivo. Inhibitors of NF-κB activation can block the
neoplastic transformation response. Both TNF and PMA
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activated NF-κB and induced cell transformation, whereas
NF-κB blockers suppressed the transformation. These
results suggest that NF-κB activation may be required for
transformation whether induced by TPA or by TNF.
Inhibition of NF-κB through adenoviral delivery of a
modified form of IκBα, a specific inhibitor of NF-κB, has
been reported to sensitize chemoresistant tumors to the
apoptotic potential of TNF-α and to the chemotherapeutic
compound CPT-11, resulting in tumor regression.
A central mediator of a wide host of target genes
regulated by the NF-κB has emerged as a molecular target
in cancer-associated bone destruction. Gordon and
coworkers investigated NF-κB-dependent mechanisms in
breast cancer cells that regulate tumor burden and
osteolysis in bone. They stably transfected cells of the
bone-seeking MDA-MB-231 breast cancer cell line with a
DN-IκBα to block NF-κB. Blockade of NF-κB signaling in
MDA-MB-231 cells decreased in vitro cell proliferation,
expression of the pro-inflammatory, bone-resorbing
cytokine interleukin-6, and in vitro bone resorption by
tumor/osteoclast
co-cultures
while
reciprocally
upregulating production of the proapoptotic enzyme
caspase-3. Dong et al. used molecular profiling of
transformed and metastatic murine squamous carcinoma
cells by differential display and cDNA microarray, which
found altered expression of multiple genes related to
growth, apoptosis, angiogenesis, and the NF-κB signaling
pathway. Loercher’s group examined the role of NF-κB in
the cumulative changes in gene expression with
transformation and progression of the murine SCC and
after switching off NF-κB by a DN-IκBα(M) by profiling
with cDNA microarray. They found that NF-κB directly or
indirectly modulated expression of programs of genes
functionally linked to proliferation, apoptosis, adhesion,
and angiogenesis. These results also provide evidence that
NF-κB is an important modulator of gene expression
programs that contribute to the malignant phenotype of
SCC.
Ⅵ.

Role of NF-κB in Tumor Metastasis

Metastasis of cancer cells is a complex process
involving multiple steps, including invasion, angiogenesis,
trafficking of cancer cells through blood vessels,
extravasations, organ-specific homing, and growth. While
MMP, UPA, and cytokines play a major role in invasion
and angiogenesis, chemokines such as SDF-1α and their
receptors such as CXCR4 are thought to play a critical role
in motility, homing, and proliferation of cancer cells at
specific metastatic sites. NF-κB signal blockade resulted in
the downregulation of prometastatic MMP-9, a UPA, and
heparanase and reciprocal upregulation of antimetastatic
TIMP-1 and -2 and PAI 2. NF-κB promotes breast cancer
cell migration and metastasis by inducing the expression of
the chemokine receptor CXCR4.
NF-κB regulates the motility of breast cancer cells by
directly upregulating the expression of CXCR4. The cell
surface expression of CXCR4 and the SDF-1α-mediated
migration are enhanced in breast cancer cells isolated from
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mammary fat pad xenografts compared with parental cells
grown in culture. A further increase in CXCR4 cell surface
expression and SDF-1α-mediated migration was observed
with cancer cells that metastasized to the lungs. Taken
together, these results implicate NF-κB in the migration
and the organ-specific homing of metastatic breast cancer
cells. Huang et al. reported that blockade of NF-κB
signaling also inhibits angiogenesis and tumorigenicity of
human ovarian cancer cells by suppressing expression of
VEGF and IL- 8.
The transcription factors p53 and NF-κB have been
implicated in apoptosis induced by DNA-damaging agents,
but the relationship between these two factors at the
molecular level is largely unknown. Downregulation of
NF-κB is required for p53-dependent apoptosis in
X-ray-irradiated mouse lymphoma cells and thymocytes.
Apoptosis-resistant mutant sublines from a radiosensitive
mouse lymphoma 3SB cell line that undergoes
p53-dependent apoptosis after X-ray irradiation were
isolated and analyzed for NF-κB activity. A similar
downregulation of NF-κB activity by X-rays was observed
in thymocytes derived from p53 wild-type and
heterozygous mice but not in thymocytes from p53
homozygous knock-out mice. These results suggest that
NF-κB inactivation is p53 dependent and is required for
X-ray-induced apoptosis in thymic lymphoma cells and
normal thymocytes.
The molecular mechanisms responsible for the
progression of malignant transformation in Barrett’s
esophagus are still poorly understood; however, the
activation of NF-κB represents the central event in the
neoplastic progression associated with Barrett’s esophagus
The increased NF-κB activity has been linked to increased
IL-8 and COX-2 expression.
Ⅶ.

Regulation of NF-kB by Dietary Agent

These observation provides evidence for a strong link
between chronic inflammation and cancer. Thus
inflammatory biomarkers as described here can be used to
monitor the progression of the disease. These biomarkers
can also be exploited to develop new anti-inflammatory
drugs to prevent and treat cancer. These drugs can also be
used as adjuvant to the currently available chemotherapy
and radiotherapy, which by themselves activate NF-κB and
mediate resistance. Numerous anti-inflammatory agents
including those identified from dietary sources have been
shown to exhibit chemopreventive activities and thus can
be used not only for prevention but also for therapy of
cancer. The lack of toxicity associated with the natural
agents combined with their cost provides additional
advantages
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